Simms Christopher Paul 4

What Happened

• Christopher Paul Simms, Chief Commercial and Business Officer of 4D Molecular Therapeutics (FDMT), was granted a derivative award covering 219,000 shares on 2026-03-25. The filing reports an acquisition price of $0.00 (total reported value $0), and the award is described in the footnote as a stock option award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-25; Filing date: 2026-03-27 (timely filing).
• Reported acquisition: 219,000 shares at $0.00 (derivative award).
• Vesting/exercise terms: Footnote states the shares underlying the stock option award vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026, fully vesting on the fourth anniversary while the grantee remains a service provider.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No 10b5-1 plan, tax withholding, cashless exercise, or late-filing flag noted in this report.

Context

• This was a grant of a stock-related award (derivative), not an open-market purchase or sale. Such grants are common for executive compensation and vest over time; they do not represent immediate buying or selling of stock unless exercised or sold later.